Figure 2.
OS at 3 years after transplant. (A) Entire cohort and stratified by (B) CK, (C) meeting the ICC for “TP53mut MN,” (D) the use of venetoclax before alloHCT, (E) pre-alloHCT BM blast percent, and (F) cytogenetic response before transplant.
OS at 3 years after transplant. (A) Entire cohort and stratified by (B) CK, (C) meeting the ICC for “TP53mut MN,” (D) the use of venetoclax before alloHCT, (E) pre-alloHCT BM blast percent, and (F) cytogenetic response before transplant.
